Share on StockTwits

bluebird bio (NASDAQ:BLUE) COO Jeffrey T. Walsh sold 1,500 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $39.86, for a total value of $59,790.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

A number of analysts have recently weighed in on BLUE shares. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of bluebird bio in a research note on Wednesday. They now have a $53.00 price target on the stock, up previously from $44.00. Separately, analysts at Wedbush raised their price target on shares of bluebird bio to $51.00 in a research note on Monday. Finally, analysts at Piper Jaffray initiated coverage on shares of bluebird bio in a research note on Friday, June 13th. They set an “overweight” rating on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $42.48.

Shares of bluebird bio (NASDAQ:BLUE) traded up 0.52% during mid-day trading on Wednesday, hitting $36.66. 379,511 shares of the company’s stock traded hands. bluebird bio has a 52 week low of $17.03 and a 52 week high of $41.75. The stock has a 50-day moving average of $23.17 and a 200-day moving average of $22.64. The company’s market cap is $898.6 million.

bluebird bio (NASDAQ:BLUE) last released its earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.12. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.23 million. Analysts expect that bluebird bio will post $-1.78 EPS for the current fiscal year.

bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.